These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8382871)

  • 1. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence of cytomegalovirus infection in kidney recipients.
    Bilgin N; Karakayali H; Moray G; Akkoç H; Turan M
    Transplant Proc; 1996 Aug; 28(4):2314-5. PubMed ID: 8769233
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients.
    Birkeland S; Gahrn-Hansen B; Andersen H; Rohr N; Larsen KE; Jørgensen A
    Transplant Proc; 1995 Dec; 27(6):3473-6. PubMed ID: 8540056
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
    Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227
    [No Abstract]   [Full Text] [Related]  

  • 14. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 16. CMV in kidney transplantation: a single center experience over 22 years.
    Nashan B; Lück R; Kliem V; Brunkhorst R; Schlitt HJ; Klempnauer J
    Clin Transpl; 1999; ():181-8. PubMed ID: 11038636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients.
    Saliba F; Eyraud D; Samuel D; David MF; Arulnaden JL; Dussaix E; Mathieu D; Bismuth H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1444-5. PubMed ID: 8382876
    [No Abstract]   [Full Text] [Related]  

  • 19. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.